title: A transcriptomic approach to elucidate the physiological significance of human cytochrome P450 2S1 in bronchial epithelial cells.
abstract: BACKGROUND
  Cytochrome P450 2S1 (CYP2S1) is an orphan P450 with an unknown biological function. Data from our laboratory and others suggest that CYP2S1 may have an important physiological role in modulating the synthesis and metabolism of bioactive lipids including prostaglandins and retinoids. CYP2S1 expression is elevated in multiple epithelial-derived cancers as well as in the chronic hyperproliferative disease psoriasis. Whether CYP2S1 expression in proliferative disease is protective, detrimental, or neutral to disease progression remains to be determined. Two human bronchial epithelial cells (BEAS-2B) were constructed to represent chronic depletion of CYP2S1 using short-hairpin RNA (shRNA) silencing directed toward the 3'UTR (759) and exon 3 (984) of the CYP2S1 gene and compared with a non-targeting shRNA control (SCRAM). Both CYP2S1 mRNA and protein were depleted by approximately 75% in stable cell lines derived from both targeted shRNA constructs (759 and 984). To elucidate the biological significance of CYP2S1, we analyzed transcriptome alterations in response to CYP2S1 depletion in human lung cells.
  
  
  RESULTS
  RNA-sequencing (RNA-seq) analysis was performed to compare the transcriptome of the control (SCRAM) and the CYP2S1-depleted (759) BEAS-2B cell lines. Transcriptomes of the replicates from the two cell lines were found to be distinct populations as determined using Principal Component Analysis and hierarchical clustering. Approximately 1000 genes were differentially expressed in response to CYP2S1 depletion. Consistent with our previous phenotypes, DAVID analysis revealed altered regulation in key pathways implicated in cell proliferation and migration. Transcriptomic profiles were also consistent with the metabolism of proposed endogenous substrates. Pathway analysis also revealed significant expression changes within mTOR signaling, a critical pathway in cell growth. To determine whether these changes manifest as altered cell size, cell diameter and volume were calculated, revealing that CYP2S1 depletion promotes cell growth in BEAS-2B cells.
  
  
  CONCLUSIONS
  These data suggest that pathway analysis of sequence-based gene expression is a powerful method to identify pathways and phenotypic alterations in response to changes in orphan enzyme expression. Our results suggest a novel role for CYP2S1-mediated metabolism in modulating BEAS-2B cell size. These findings warrant further studies on CYP2S1 regulated pathways to elucidate potential substrates of CYP2S1.
authors.affiliation: Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA. aaronrow@nmsu.edu.
authors.forename: Thushara W
authors.initials: TW
authors.lastname: Madanayake
authors.forename: Ingrid E
authors.initials: IE
authors.lastname: Lindquist
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Devitt
authors.forename: Joann
authors.initials: J
authors.lastname: Mudge
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Rowland
mesh_terms: D016718:Arachidonic Acid / Q000378:metabolism; D002460:Cell Line; D048429:Cell Size; D016000:Cluster Analysis; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D004847:Epithelial Cells / Q000378:metabolism*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D020868:Gene Silencing; D006801:Humans; D050356:Lipid Metabolism; D010641:Phenotype; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D020545:Respiratory Mucosa / Q000378:metabolism*; D017423:Sequence Analysis, RNA; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D059467:Transcriptome; D014801:Vitamin A / Q000378:metabolism
chemical_list: D034741:RNA, Small Interfering; D014801:Vitamin A; D016718:Arachidonic Acid; D003577:Cytochrome P-450 Enzyme System; C422564:CYP2S1 protein, human; D058570:TOR Serine-Threonine Kinases